The FDA has approved the antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; Datroway) for adult patients with ...
Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American ...
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® ...
GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...
CHICAGO -- Use of GLP-1 receptor agonists in patients with four solid tumor types was significantly associated with lower ...
Introduction Serum chloride has been recently recognised as a predictor of short-term mortality in patients hospitalised with ...
Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...
Investigators analyzed HCC incidence and incidence-based mortality trends by sex, race, and ethnicity, and stage at diagnosis to identify disparities between urban and rural patients.
Hypertension in men and an increasing number of cardiometabolic criteria were associated with higher risk for advanced fibrosis and at-risk MASH.
AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
A multianalyte blood test demonstrated superior sensitivity and noninferior specificity compared with ultrasound for hepatocellular carcinoma (HCC) detection in patients with cirrhosis, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results